SCHEMBL28518798

SCHEMBL28518798

CC(C)(C)OC(=O)NCc1cnn(Cc2cc(F)c(F)c(F)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.43
HDAC3 O15379 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
TAS2R8 Q9NYW2 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
POLB P06746 1/20 0.39
RORC P51449 1/20 0.38
NAMPT P43490 2/20 0.38
KLKB1 P03952 6/20 0.37
GRM2 Q14416 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 2/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KLK1 P06870 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075754 0.83 CACNA1H (0.49) SCDHDAC3HDAC8NCOR2TAS2R8
SCHEMBL24973943 0.82 SCD (0.58) SCDHDAC3HDAC8NCOR2TAS2R8
SCHEMBL21492545 0.82 KLKB1 (0.42) POLBKLKB1MAPTKLK1
SCHEMBL31535814 0.81 CACNA1H (0.41) SCDHDAC3HDAC8NCOR2TAS2R8
SCHEMBL30545729 0.80 CACNA1H (0.40) SCDTAS2R8POLBRORCKLKB1
SCHEMBL26076234 0.80 CACNA1H (0.40) SCDTAS2R8POLBRORCKLKB1
SCHEMBL26074028 0.80 SCD (0.42) SCDHDAC3HDAC8NCOR2TAS2R8
SCHEMBL21432150 0.80 GAA (0.55) SCDHDAC3HDAC8NCOR2NAMPT
SCHEMBL30060309 0.79 HDAC3 (0.46) SCDHDAC3HDAC8NCOR2TAS2R8
SCHEMBL31535663 0.79 CACNA1H (0.38) SCDHDAC3HDAC8NCOR2TAS2R8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384790-B2 Pteridinone compounds and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-08-12 US disclosed
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-10-05 US disclosed
US-11572364-B2 Pteridinone compounds and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-02-07 US disclosed
US-20220363685-A1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2022-11-17 US disclosed
CN-112218865-A Pteridinone compounds and uses thereof 沃泰克斯药物股份有限公司 2021-01-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572364-B2 Pteridinone compounds and uses thereof DPYD, PKD1, TYMP SCD 2906/4885HDAC3 1779/4885HDAC8 896/4885
US-20220363685-A1 PTERIDINONE COMPOUNDS AND USES THEREOF DPYD, PKD1, TYMP SCD 2906/4885HDAC3 1779/4885HDAC8 896/4885
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF DPYD, PKD1, TYMP SCD 2906/4885HDAC3 1779/4885HDAC8 896/4885
US-12384790-B2 Pteridinone compounds and uses thereof DPYD, PKD1, TYMP SCD 2906/4885HDAC3 1779/4885HDAC8 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.